Back to Directory
ImmuPharma
London
Founded 2000
Clinical-stage peptide therapeutics for autoimmune and infectious disease
ImmuPharma is a clinical-stage biopharmaceutical company developing peptide-based therapeutics and precision diagnostics for autoimmune disease, infectious disease and metabolic disorders.
Its lead candidate, a first-in-class immunormalizer for lupus, has completed a Phase III pivotal trial, aiming to restore normal immune function rather than broadly suppress it.
The pipeline also includes anti-infective candidates addressing antimicrobial resistance and a candidate for Type 1 diabetes.
ImmuPharma is listed on AIM, with its R&D conducted through a French subsidiary.